Vanda Pharmaceuticals (VNDA) Operating Income Growth (3y) (2013 - 2026)
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -181.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -181.29% |
| Mar 31, 2026 | -200.23% |
| Dec 31, 2025 | -100.73% |
| Sep 30, 2025 | -115.48% |
| Jun 30, 2025 | -135.88% |
| Mar 31, 2025 | -74.90% |
| Dec 31, 2024 | -47.21% |
| Sep 30, 2024 | -44.49% |
| Jun 30, 2024 | -41.29% |
| Mar 31, 2024 | -42.49% |
| Dec 31, 2023 | -38.88% |
| Sep 30, 2023 | -40.51% |
| Jun 30, 2023 | -32.24% |
| Mar 31, 2023 | 162.23% |
| Dec 31, 2022 | 16.04% |
| Sep 30, 2022 | -28.65% |
| Jun 30, 2022 | -29.54% |
| Mar 31, 2022 | -54.31% |
| Dec 31, 2021 | -1.91% |
| Sep 30, 2021 | 20.18% |